Zidovudine

Generic Name: Zidovudine

Brand Names: Combivir, Retrovir, Trizivir

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₃N_₅O_₄

CAS Number: 30516-87-1

Unique Ingredient Identifier: 4B9XT59T7S

Background: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]

Indication: Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.

Associated Conditions: HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission

Associated Therapies: -

Clinical Trials

An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Registration Number: NCT00002023

Locations: 🇺🇸
Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States

A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant

Not Applicable

Completed

Conditions: Lymphoma, Non-Hodgkin
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Registration Number: NCT00002284

Locations: 🇺🇸
Johns Hopkins Hemapheresis Treatment Ctr, Baltimore, Maryland, United States

A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Pharmacia and Upjohn

Target Recruit Count: 32

Registration Number: NCT00002236

Locations: 🇺🇸
UCSF AIDS Research Institute, San Francisco, California, United States
🇺🇸
Saint Luke's - Roosevelt Hosp Ctr, New York, New York, United States
🇺🇸
Anderson Clinical Research, Pittsburgh, Pennsylvania, United States

and more 3 locations

A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 140

Registration Number: NCT00002162

Locations: 🇺🇸
UCD Med Ctr, Sacramento, California, United States
🇺🇸
Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸
UCSD Treatment Ctr, San Diego, California, United States

and more 24 locations

A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Genelabs Technologies

Registration Number: NCT00001989

Locations: 🇺🇸
UCSF - San Francisco Gen Hosp, San Francisco, California, United States
🇺🇸
Miami Veterans Administration Med Ctr, Miami, Florida, United States
🇺🇸
Dr Larry A Waites, San Francisco, California, United States

and more 5 locations

Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Registration Number: NCT00002063

Locations: 🇺🇸
Dr Gordon Dickinson, Miami, Florida, United States
🇺🇸
Dr Gigi Diamond / New York Veterans Administration, New York, New York, United States
🇺🇸
Veterans Affairs Med Ctr / Admin Only / Not For Patient Care, Durham, North Carolina, United States

and more 5 locations

A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Target Recruit Count: 256

Registration Number: NCT00002086

Locations: 🇺🇸
Univ of Kansas School of Medicine, Wichita, Kansas, United States
🇺🇸
Marin County Specialty Clinic, San Rafael, California, United States
🇺🇸
Stratogen of South Florida, Miami Beach, Florida, United States

and more 10 locations

A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC Patients

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Registration Number: NCT00002013

Locations: 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 120

Registration Number: NCT00002184

Locations: 🇺🇸
Krauss Med Partners / Dept of Research and Development, Los Angeles, California, United States
🇺🇸
UCLA Care Ctr, Los Angeles, California, United States
🇵🇷
Hosp Regional de Ponce - Area Vieja, Ponce, Puerto Rico

and more 12 locations

A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 40

Registration Number: NCT00002367

Locations: 🇺🇸
AIDS Healthcare Foundation Labs, Los Angeles, California, United States
🇺🇸
Urgent Care Ctr / North Broward Hosp District, Fort Lauderdale, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy